COVID-19 Vaccine 3rd Dose for Immunocompromised

3rd COVID-19 Vaccine Dose Recommended for Immunocompromised Patients

People who are moderately to severely immunocompromised are especially vulnerable to COVID-19 because they are more at risk of serious, prolonged illness. The CDC recommends that moderately to severely immunocompromised persons receive an additional COVID-19 vaccine does if they received the Pfizer or Moderna vaccine.

How to obtain a 3rd dose of COVID-19 vaccine if eligible:

  • Inquire about the 3rd dose at a scheduled appointment.
  • Or, contact us via your patient portal account to inquire about eligibility.

Please note: The 3rd dose should be the same vaccine product (Pfizer for Pfizer, or Moderna for Moderna) as the initial 2-dose COVID-19 vaccine series. The Family Health Centers can offer a 3rd dose of the Pfizer vaccine at this time. The additional dose must be administered 28 days+ after the initial COVID-19 vaccine series. This does not apply to patients who received the single-dose Johnson & Johnson COVID-19 vaccine – please stay tuned for more information if you received the J&J COVID-19 vaccine.

You are eligible for the 3rd Vaccine Dose if one or more of the following applies to you:

CDC Vaccines Protect Image

1. Been receiving active cancer treatment for tumors or cancers of the blood
2. Received an organ transplant and are taking medicine to suppress the immune system
3. Received a stem cell transplant within the last 2 years
4. Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
5. Advanced or untreated HIV infection (i.e., AIDS)
6. Active treatment with high-dose steroids or other drugs that may suppress your immune response, including:
o prednisone (Deltasone, Orasone)
o dexamethasone
o budesonide (Entocort EC)
o prednisolone (Millipred)
o tofacitinib (Xeljanz)
o cyclosporine (Neoral, Sandimmune, SangCya)
o tacrolimus (Astagraf XL, Envarsus XR, Prograf)
o sirolimus (Rapamune)
o everolimus (Afinitor, Zortress)
o azathioprine (Azasan, Imuran)
o leflunomide (Arava)
o mycophenolate (CellCept, Myfortic)
o abatacept (Orencia)
o adalimumab (Humira)
o anakinra (Kineret)
o certolizumab (Cimzia)
o etanercept (Enbrel)
o golimumab (Simponi)
o infliximab (Remicade)
o ixekizumab (Taltz)
o natalizumab (Tysabri)
o rituximab (Rituxan)
o secukinumab (Cosentyx)
o tocilizumab (Actemra)
o ustekinumab (Stelara)
o vedolizumab (Entyvio)
o basiliximab (Simulect)
o daclizumab (Zinbryta)